Protagonist Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Protagonist Therapeutics

09/05/2022 22:03

* Protagonist Therapeutics Inc  PTGX.OQ  reported a
quarterly
adjusted loss of 43 cents​​ per share for the quarter ended in
March. The mean expectation of six analysts for the quarter was
for a loss of 63 cents per share.
    * Revenue rose 315.6% to $25.72 million from a year ago; 
analysts
expected $17.05 million. 
    * Protagonist Therapeutics Inc's reported EPS for the
quarter was
a loss of 43 cents​.
    * The mean earnings estimate of analysts had risen by
about 12.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Protagonist Therapeutics Inc shares had fallen by 61.6%
this
quarter and lost 73.4% so far this year.
    * The company reported a quarterly loss of $20.93 million.
    * Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is $45.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 9 at 09:03 p.m.  ​All
figures in US dollars unless otherwise stated